Mallinckrodt Plc Ordinary Share (MNK) 86.89 $MNK
NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 6:05PM CDT
The EMDAC of the FDA recommended the approval of NPS Pharmaceuticals' Natpara.
Can Mallinckrodt public limited (MNK) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 7:54AM CDT
Mallinckrodt public limited could be a great candidate for another beat after a solid performance in the last two quarters.
Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:20PM CDT
Mylan (MYL) is all set to acquire the U.S. commercialization, marketing and intellectual property rights to Arixtra injection from Aspen.
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).
Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
Maharathi Basu - Zacks Investment Research - Wed Sep 10, 3:30PM CDT
Emergent BioSolutions (EBS) secured a federal contract worth up to $29 million.
Endocyte (ECYT) Worth Watching: Stock Soars 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:46AM CDT
Endocyte (ECYT) was a big mover last session, with shares rising just over 17% on the day.
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.
Mallinckrodt (MNK) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:39AM CDT
Mallinckrodt (MNK) Shares March Higher, Can It Continue?
Technical Snapshot on Pharma Stocks - Allergan, Akorn, Mallinckrodt, Mylan, and AVANIR Pharma
PR Newswire - Mon Sep 08, 8:25AM CDT
On Friday, September 5, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, with the index also advancing 6.70% in the last three months. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Mallinckrodt PLC (NYSE: MNK), Mylan Inc. (NASDAQ: MYL), and AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR). Free research on these five companies can be accessed at:
IntelliPharmaCeutics (IPCI) in Focus: Stock Gains 15.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 8:25AM CDT
IntelliPharmaCeutics (IPCI) was a big mover last session, with shares rising nearly 16% on the day.
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth
PR Newswire - Mon Sep 08, 7:55AM CDT
Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.
New REMS Education Program Helps Increase Safe, Responsible Use of Opioid Analgesics for Pain Relief
Business Wire - Mon Sep 08, 7:01AM CDT
Assessments of a novel Continuing Medical Education (CME) initiative showed meaningful changes in opioid prescribing behavior and improvements in pain-patient outcomes. These assessments of REMEDIES (Risk Evaluation and Mitigation Strategies - An Employer-Driven CME Initiative for Efficacy and Safety) - were presented this past week at PAINWeek, the nation's largest conference for clinicians with an interest in pain management.
Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:05PM CDT
Mallinckrodt plc (MNK) announced encouraging results from a phase III efficacy study on its pain candidate, MNK-155.
Mallinckrodt Pharmaceuticals Presents 11 Posters with Data on Investigational Opioid, MNK-155, and XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended Release Tablets (CII) at PAINWeek 2014
Business Wire - Fri Sep 05, 8:00AM CDT
Mallinckrodt (NYSE: MNK) presented 11 posters with data on its investigational opioid, MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, and recently FDA-approved XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), at PAINWeek, September 2-6 in Las Vegas, Nevada. The studies examined the compound's efficacy, safety, abuse-related characteristics and release/delivery profiles with immediate- and extended-release components.
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.
Today's Momo Momentum Stock To Watch: Mallinckrodt (MNK)
at The Street - Thu Sep 04, 8:50AM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate
Tetraphase Pharmaceuticals (TTPH) in Focus: Stock Gains 14.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:46AM CDT
Tetraphase Pharmaceuticals (TTPH) was a big mover last session, with shares rising nearly 15% on the day.
10 Stocks Billionaire John Paulson Loves in 2014
at The Street - Thu Sep 04, 8:33AM CDT
Here's a look at 10 stocks that Paulson & Co. bought in the most recently reported quarter.
Mallinckrodt Pharmaceutical's MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination, Shows Efficacy in Phase 3 Acute Pain Trial
Business Wire - Thu Sep 04, 8:00AM CDT
Mallinckrodt (NYSE: MNK) today reported that a Phase 3 efficacy trial of investigational MNK-155 met the study's primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy (p<0.001). This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014, a national conference on pain for frontline practitioners, held in Las Vegas, Nevada September 2-6, 2014.
Merck KGaA in Deal with S-TARget, Allergy Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:50PM CDT
Merck KGaA's (MKGAF) Allergopharma, strikes deal with S-TARget therapeutics for developing a new generation of therapies for allergies using S-TIR technology.
NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 6:05PM CDT
The EMDAC of the FDA recommended the approval of NPS Pharmaceuticals' Natpara.
Can Mallinckrodt public limited (MNK) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 7:54AM CDT
Mallinckrodt public limited could be a great candidate for another beat after a solid performance in the last two quarters.
Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:20PM CDT
Mylan (MYL) is all set to acquire the U.S. commercialization, marketing and intellectual property rights to Arixtra injection from Aspen.
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).
Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
Maharathi Basu - Zacks Investment Research - Wed Sep 10, 3:30PM CDT
Emergent BioSolutions (EBS) secured a federal contract worth up to $29 million.
Endocyte (ECYT) Worth Watching: Stock Soars 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:46AM CDT
Endocyte (ECYT) was a big mover last session, with shares rising just over 17% on the day.
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.
Mallinckrodt (MNK) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:39AM CDT
Mallinckrodt (MNK) Shares March Higher, Can It Continue?
Technical Snapshot on Pharma Stocks - Allergan, Akorn, Mallinckrodt, Mylan, and AVANIR Pharma
PR Newswire - Mon Sep 08, 8:25AM CDT
On Friday, September 5, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, with the index also advancing 6.70% in the last three months. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Mallinckrodt PLC (NYSE: MNK), Mylan Inc. (NASDAQ: MYL), and AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR). Free research on these five companies can be accessed at:
IntelliPharmaCeutics (IPCI) in Focus: Stock Gains 15.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 8:25AM CDT
IntelliPharmaCeutics (IPCI) was a big mover last session, with shares rising nearly 16% on the day.
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth
PR Newswire - Mon Sep 08, 7:55AM CDT
Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.
New REMS Education Program Helps Increase Safe, Responsible Use of Opioid Analgesics for Pain Relief
Business Wire - Mon Sep 08, 7:01AM CDT
Assessments of a novel Continuing Medical Education (CME) initiative showed meaningful changes in opioid prescribing behavior and improvements in pain-patient outcomes. These assessments of REMEDIES (Risk Evaluation and Mitigation Strategies - An Employer-Driven CME Initiative for Efficacy and Safety) - were presented this past week at PAINWeek, the nation's largest conference for clinicians with an interest in pain management.
Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:05PM CDT
Mallinckrodt plc (MNK) announced encouraging results from a phase III efficacy study on its pain candidate, MNK-155.
Mallinckrodt Pharmaceuticals Presents 11 Posters with Data on Investigational Opioid, MNK-155, and XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended Release Tablets (CII) at PAINWeek 2014
Business Wire - Fri Sep 05, 8:00AM CDT
Mallinckrodt (NYSE: MNK) presented 11 posters with data on its investigational opioid, MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, and recently FDA-approved XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), at PAINWeek, September 2-6 in Las Vegas, Nevada. The studies examined the compound's efficacy, safety, abuse-related characteristics and release/delivery profiles with immediate- and extended-release components.
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.
Today's Momo Momentum Stock To Watch: Mallinckrodt (MNK)
at The Street - Thu Sep 04, 8:50AM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate
Tetraphase Pharmaceuticals (TTPH) in Focus: Stock Gains 14.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:46AM CDT
Tetraphase Pharmaceuticals (TTPH) was a big mover last session, with shares rising nearly 15% on the day.
10 Stocks Billionaire John Paulson Loves in 2014
at The Street - Thu Sep 04, 8:33AM CDT
Here's a look at 10 stocks that Paulson & Co. bought in the most recently reported quarter.
Mallinckrodt Pharmaceutical's MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination, Shows Efficacy in Phase 3 Acute Pain Trial
Business Wire - Thu Sep 04, 8:00AM CDT
Mallinckrodt (NYSE: MNK) today reported that a Phase 3 efficacy trial of investigational MNK-155 met the study's primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy (p<0.001). This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014, a national conference on pain for frontline practitioners, held in Las Vegas, Nevada September 2-6, 2014.
Merck KGaA in Deal with S-TARget, Allergy Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:50PM CDT
Merck KGaA's (MKGAF) Allergopharma, strikes deal with S-TARget therapeutics for developing a new generation of therapies for allergies using S-TIR technology.
